Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Sci Signal. 2022 Aug 9;15(746):eadc9816. doi: 10.1126/scisignal.adc9816.
Although oncogenic driver mutations in occur in 20% of cancers, heterogeneity in the biologic outputs of different RAS mutants has hampered efforts to develop effective treatments for -mutated cancers. In this issue of , Huynh . show that even among KRAS mutants, the specific amino acid that is substituted substantially affects mutant KRAS biologic activity and oncogenicity.
虽然 发生的致癌驱动基因突变在 20%的癌症中存在，但不同 RAS 突变体的生物学产物的异质性阻碍了开发针对 -突变癌症的有效治疗方法的努力。在本期的 杂志中，Huynh 等人表明，即使在 KRAS 突变体中，取代的特定氨基酸也会极大地影响突变型 KRAS 的生物学活性和致癌性。
